People: Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

2.88GBp
11 Jul 2014
Price Change (% chg)

0.00p (+0.00%)
Prev Close
2.88p
Open
2.88p
Day's High
--
Day's Low
--
Volume
1,153,314
Avg. Vol
1,554,495
52-wk High
3.80p
52-wk Low
1.30p

Search Stocks

Summary

Name Age Since Current Position

Nicholas Rodgers

54 2011 Non-Executive Independent Chairman of the Board

John Dawson

54 2008 Chief Executive Officer, Executive Director

Andrew Heath

64 2011 Non-Executive Deputy Chairman of the Board, Senior Independent Director

Tim Watts

55 2012 Chief Financial Officer, Company Secretary, Executive Director

Peter Nolan

60 2002 Senior Vice President - Commercial Development, Executive Director

Madhu Davies

2013 Chief Medical Officer

Martin Diggle

50 2012 Non-Executive Director

Paul Blake

65 2010 Non-Executive Independent Director

Biographies

Name Description

Nicholas Rodgers

Mr. Nicholas Rodgers is Non-Executive Independent Chairman of the Board of Oxford Biomedica Plc. He was appointed to Oxford BioMedica’s Board in March 2004 and was appointed Chairman in May 2011. Mr Rodgers is a former investment banker with considerable experience in the life sciences sector. He is now Chief Executive of Ipso Ventures plc, an intellectual property commercialisation business, having been Head of Life Sciences and joint-Head of Corporate Finance at Evolution Beeson Gregory until December 2003. Mr. Rodgers joined Beeson Gregory in 1989 from accountants Ernst & Young, having also worked in the listing department of the London Stock Exchange. He is Chairman of Oxford BioMedica’s Audit and Nomination committees.

John Dawson

Mr. John Dawson is Chief Executive Officer, Executive Director of Oxford BioMedica Plc. He joined Oxford BioMedica’s Board as a non-executive Director on 1 August 2008. He was then appointed Chief Executive Officer on 13 October 2008, having served as Acting Chief Executive Officer since 29 August 2008. From 1996 to 2007, Mr Dawson held senior management positions in the European operations of Cephalon Inc. including, from 2005, a management board position as Chief Financial Officer and Head of Business Development Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to revenue of several hundred million US dollars. In 2005, Mr Dawson led the US$360 million acquisition of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited.

Andrew Heath

Dr. Andrew J. Heath, M.D., Ph.D., is Non-Executive Deputy Chairman of the Board, Senior Independent Director of Oxford BioMedica PLC. He was appointed to Oxford BioMedica’s Board in January 2010 and was appointed Deputy Chairman and Senior Independent Director in May 2011. Dr. Heath is a healthcare and biopharmaceutical executive with knowledge of US and UK capital markets and international experience in marketing and sales, R & D and business development. He was Chief Executive Officer of Protherics plc from 1997 to 2008, taking the Company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, Dr. Heath was President and Chief Executive Officer of Aerogen Inc, and previously held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director. He is currently a non-executive director of XL TechGroup Inc, Anew Inc, Pioneer Technology Inc, and is a director of the BioIndustry Association.

Tim Watts

Mr. Tim Watts is Chief Financial Officer, Company Secretary, Executive Director of Oxford BioMedica PLC. He has over 30 years' experience in multinational and entrepreneurial businesses. Tim qualified as a chartered accountant, beginning his career with Coopers & Lybrand before moving to H J Heinz, the food producer. In 1985 he joined ICI, initially in the corporate headquarters and from 1990 in the pharmaceuticals division, eventually rising to be Finance Director of the Zeneca Pharmaceuticals business. Following the merger of Astra and Zeneca, Tim became Group Financial Controller of AstraZeneca PLC in 2001. In 2007 he left AstraZeneca to become Chief Financial Officer at Archimedes Pharma. He has a proven track record in the industry, including managing corporate transactions, M&A activity, fundraising and strategic implementation.

Peter Nolan

Mr. Peter Nolan is Senior Vice President - Commercial Development, Executive Director of Oxford Biomedica Plc. He was appointed to Oxford BioMedica’s Board in May 2002, having been a senior member of the Company since its foundation. He is also a Director of the UK BioIndustry Association and is a past Chairman of the Oxfordshire Bioscience Network. Prior to joining Oxford BioMedica, Mr Nolan served as Head of the Biotechnology Unit at the UK Department of Trade & Industry for eight years. In that role he was responsible for establishing and managing complex collaborative research programmes involving industry, research councils and other government departments. Previously, Mr Nolan held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory in London where he was a senior forensic scientist.

Madhu Davies

Dr. Madhu Davies has been appointed as Chief Medical Officer of Oxford BioMedica PLC., effective June 7, 2013. Dr. Davies, MB ChB DRCOG DGM MRCGP FFPM CSci MBA (Cantab) is a medically qualified physician with more than 25 years' industry experience. Previously, Dr. Davies has been responsible for the strategic development and management of products from concept through to registration, launch and lifecycle management across multiple therapeutic areas. Dr. Davies has also implemented global clinical development programmes from Phase I to III, through to market and has a track record of clinical evaluation, product registration and medical marketing both in Europe and the USA.

Martin Diggle

Mr. Martin Diggle is Non-Executive Director of Oxford BioMedica PLC. Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Oxford BioMedica’s shareholder. An investment professional with over 29 years’ experience in investment banking and fund management, Martin has first-hand knowledge of the global financial markets. Martin is an experience in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003. He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade.

Paul Blake

Dr. Paul Blake, M.D., is Non-Executive Independent Director of Oxford BioMedica Plc., since January 2010. Dr. Blake has over 30 years’ international pharmaceutical/ biotech experience, and is currently Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endrocrine therapy. From 2001 to 2006, he held senior management positions at Cephalon Inc, including executive vice president, Worldwide Medical & Regulatory Operations from 2005. Dr Blake’s previous positions include senior vice president and medical director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals. He gained his medical degree from the London University, Royal Free Hospital. Dr Blake is Chairman of Oxford BioMedica’s Remuneration Committee.

Basic Compensation

Name Fiscal Year Total

Nicholas Rodgers

75,000

John Dawson

401,480

Andrew Heath

--

Tim Watts

222,512

Peter Nolan

202,858

Madhu Davies

--

Martin Diggle

--

Paul Blake

--
As Of 30 Dec 2012

Options Compensation

Search Stocks